1st Dept of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital
Welcome,         Profile    Billing    Logout  
 2 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nannini, Esteban Ca
NCT04405271: TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)

Not yet recruiting
3
1378
RoW
Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet, FTC/TAF, Placebo, Placebo comparator
Hospital Italiano de Buenos Aires, Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious Diseases)
Healthcare Workers, COVID-19, SARS-CoV 2
11/20
11/20
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Terminated
3
409
Europe, US, RoW
Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo
Dompé Farmaceutici S.p.A
Infectious Pneumonia, Severe COVID-19
09/24
09/24
NCT01056185: Respiratory Virus Hospitalization Study (FLU 003 Plus)

Completed
N/A
1000
Europe, US, RoW
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Clinical & Translational Science Institute, University of Minnesota
Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
08/24
08/24
Kalomenidis, Ioannis
INSIGHT12, NCT04910269: Outpatient Treatment With Anti-Coronavirus Immunoglobulin

Recruiting
3
820
Europe, US, RoW
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
COVID, SARS-CoV2 Infection, Covid19
08/26
08/26
NCT05032066: A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis

Calendar Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis
Active, not recruiting
2
153
Europe, Canada, Japan, US, RoW
HZN-825, Placebo
Amgen
Idiopathic Pulmonary Fibrosis
07/24
07/25
NCT01056185: Respiratory Virus Hospitalization Study (FLU 003 Plus)

Completed
N/A
1000
Europe, US, RoW
University of Minnesota, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Clinical & Translational Science Institute, University of Minnesota
Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
08/24
08/24

Download Options